Physician profile
Nathan Eric Usry
NPI 1679151120
$3,195.34
in general payments reported to CMS, 2019-2025
22 companies · $1,171 in 2025
The $1,171 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $249 · 2022: $305 · 2023: $150 · 2024: $1,320 · 2025: $1,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,542 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,542.38 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $909.48 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $229.54 | 2024 | Xarelto |
| Lilly USA, LLC | $224.82 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $205.85 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $202.83 | 2024-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $201.10 | 2024-2025 | Entyvio, Gattex, Eohilia |
| Genzyme Corporation | $165.34 | 2024-2025 | |
| Intercept Pharmaceuticals, INC. | $162.46 | 2025 | |
| Medtronic, INC. | $149.90 | 2023 | Manoscan |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $137.42 | 2021-2025 | Relistor |
| Gilead Sciences, INC. | $132.02 | 2024-2025 | Livdelzi |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.53 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $53.58 | 2024-2025 | Dupixent |
| Erbe USA INC | $40.00 | 2025 | Vio3 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $38.87 | 2022-2025 | Wegovy |
| Ardelyx, INC. | $36.84 | 2025 | Ibsrela |
| Amgen INC. | $21.46 | 2025 | Uplizna |
| Merck Sharp & Dohme LLC | $21.33 | 2024 | Dificid |
| Pfizer INC. | $18.44 | 2025 | |
| Celltrion USA INC. | $14.93 | 2024 | Vegzelma |
| Aimmune Therapeutics, INC. | $14.60 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Usry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.